Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for synthesizing teriflunomide

A synthesis method and technology of teriflunomide are applied in the field of pharmaceutical synthesis, and can solve the problems of being unsuitable for large-scale industrial production, inflammable and explosive, etc.

Inactive Publication Date: 2015-06-10
HYBIO PHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Acetic anhydride is a precursor reagent, and NaH is flammable and explosive, so it is not suitable for large-scale industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for synthesizing teriflunomide
  • Method for synthesizing teriflunomide
  • Method for synthesizing teriflunomide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Preparation of teriflunomide with cyanoacetic acid as initial raw material

[0052] Add 3.0 g of cyanoacetic acid to 130 mL of thionyl chloride, reflux at 75°C for 2 hours, remove excess thionyl chloride on a rotary evaporator to obtain a yellow oil, add anhydrous dichloromethane to dissolve, and obtain a yellow oil Anhydrous dichloromethane solution, set aside.

[0053] Dissolve 4.40 mL of p-trifluoromethylaniline in anhydrous dichloromethane, add 7.32 mL of triethylamine, and add the obtained yellow oil in anhydrous dichloromethane dropwise at 0°C. Stir overnight at °C, remove the solvent, and recrystallize the crude product from ethanol to obtain 4.51 g of solid, with a yield of 57%. Gained solid is carried out proton nuclear magnetic resonance spectrum detection, gained data is 1 H-NMR(400MHz,DMSO)δ10.64(s,1H),7.76(d,J=8.7Hz,2H),7.70(d,J=8.9Hz,2H),3.96(s,2H), such as figure 1 As shown, the measured data is consistent with the 2-cyano-N-(4-trifluoromethy...

Embodiment 2

[0055] Example 2 The preparation of teriflunomide with cyanoacetic acid as the initial raw material

[0056] Take 3.0 g of cyanoacetic acid and add it to 130 mL of thionyl chloride, reflux at 75 ° C for 1 h, remove excess thionyl chloride on a rotary evaporator to obtain a yellow oil, add chloroform to dissolve, and obtain a chloroform solution of the yellow oil. spare.

[0057] Dissolve 4.40 mL of p-trifluoromethylaniline in chloroform, add 7.32 mL of triethylamine, and add dropwise at 0°C to obtain a solution of yellow oil in chloroform. After the dropwise addition, stir at 0-50°C for 1 h, The solvent was removed, and the crude product was recrystallized from ethanol to obtain 4.82 g of solid, with a yield of 61%. Gained solid is carried out proton nuclear magnetic resonance spectrum detection, gained data is 1 H-NMR (400MHz, DMSO) δ10.64(s, 1H), 7.76(d, J=8.7Hz, 2H), 7.70(d, J=8.9Hz, 2H), 3.96(s, 2H), measured The data are consistent with the 2-cyano-N-(4-trifluoromethyl...

Embodiment 3

[0059] Example 3 Preparation of teriflunomide with cyanoacetic acid as initial raw material

[0060] Take 3.0 g of cyanoacetic acid and add it to 130 mL of thionyl chloride, reflux at 85 ° C for 8 h, remove excess thionyl chloride on a rotary evaporator to obtain a yellow oil, add carbon tetrachloride to dissolve, and obtain a yellow oil Carbon tetrachloride solution, spare.

[0061] Dissolve 4.40 mL of p-trifluoromethylaniline in carbon tetrachloride, add 7.32 mL of triethylamine, and add dropwise at 0°C to obtain a solution of yellow oil in carbon tetrachloride. After stirring for 2 h, the solvent was removed, and the crude product was recrystallized from ethanol to obtain 4.22 g of solid, with a yield of 53%. Gained solid is carried out proton nuclear magnetic resonance spectrum detection, gained data is 1 H-NMR (400MHz, DMSO) δ10.64(s, 1H), 7.76(d, J=8.7Hz, 2H), 7.70(d, J=8.9Hz, 2H), 3.96(s, 2H), measured The data are consistent with the 2-cyano-N-(4-trifluoromethylphen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of drug synthesis, and particularly relates to a method for synthesizing teriflunomide. The method comprises the following step: by taking 2-cyano-group-N-(4-trifluoromethyl phenyl)-acetamide and acetyl chloride as raw materials, carrying out carbanion nucleophilic substitution reaction in the presence of alkali used as a catalyst to generate the teriflunomide, wherein the alkali is any one or a mixture of more than two of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, triethylamine, diisopropyl ethylamine, 1,8-diazabicyclo[5.4.0]C11-7-alkene, sodium hydrogen carbonate, potassium hydrogen carbonate, potassium phosphate, potassium dihydrogen phosphate or sodium sulfite. According to the method, sodium hydroxide is introduced to isothermally participate in reaction with alkali and acetyl chloride, so that the usage of a dangerous chemical is prevented; in addition, the reaction condition is moderate, so that the industrial production is facilitated.

Description

technical field [0001] The invention relates to the technical field of medicine synthesis, in particular to a synthesis method of teriflunomide. Background technique [0002] Teriflunomide, the chemical name is (Z)-2-cyano-3-hydroxy-N-(4-trifluoromethylphenyl)-2-butenamide, and its structural formula is shown in Formula I. Teriflunomide is an active metabolite of leflunomide, a dihydroorotate dehydrogenase (DHODH) inhibitor, and belongs to immunomodulatory drugs. Teriflunomide was developed by Sanofi-Aventis and was approved by the FDA for marketing on September 12, 2012. It is mainly used for the treatment of multiple sclerosis (MS). Multiple sclerosis is a chronic, inflammatory, demyelinating central nervous system disease that can cause a variety of symptoms that can lead to mobility impairment and even disability in severe cases. The listing of teriflunomide provides more options for the treatment of multiple sclerosis. [0003] [0004] Formula Ⅰ [0005] The pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C255/23C07C253/30
Inventor 李国弢刘斌马亚平袁建成
Owner HYBIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com